Transplant recipients and immunocompromised patients desperately need protection against Epstein-Barr virus, which drives dangerous lymphomas and complicates recovery when immune systems cannot mount adequate responses. Current treatment options remain frustratingly limited despite EBV's role in multiple cancers and neurological conditions.
Scientists have engineered fully human antibodies that successfully prevent EBV from infecting cells by blocking two critical viral proteins: gp350 and gp42. Using transgenic mice designed to produce human-compatible antibodies, researchers generated ten distinct therapeutic candidates. The gp42-targeting antibody provided complete protection in humanized mouse models, while the gp350 antibody offered partial defense. These proteins represent the virus's key entry mechanisms—gp350 binds complement receptors while gp42 engages HLA class II molecules to trigger cellular fusion.
This advance addresses a fundamental limitation in EBV therapeutics: previous antibodies were derived from non-human sources, creating immunogenicity concerns that restricted clinical application. The transgenic mouse platform bypasses this obstacle entirely, producing antibodies that human immune systems should readily tolerate. Structural analysis revealed previously unknown vulnerability sites on both viral targets, potentially informing future vaccine strategies. While promising, these findings require validation in human trials to confirm safety and efficacy. The research represents incremental but meaningful progress toward addressing EBV-related diseases, particularly for high-risk populations where current supportive care often proves inadequate against aggressive lymphoproliferative disorders.